MOST Plus

My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors

Open at Paris since : 24/09/2014
Target : Adult
Phase : Phase II

Trial description

This trial evaluates the efficacy of 4 oral targeted therapies (everolimus, sorafenib, pazopanib, and nilotinib) in patients with any kind of cancer whose harbour the matching targets of these drugs.

Url of the trial

Main investigator

ZAHRA CASTEL AJGAL

Médecin

Contact